Fulgent Genetics (FLGT) Accumulated Expenses (2015 - 2026)

Fulgent Genetics has reported Accumulated Expenses for 12 years, with the latest figure at $23.5 million in Q2 2026.

• Quarterly Accumulated Expenses rose 8.33% year-over-year to $23.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $23.5 million (up 8.33% YoY) and the FY2025 annual result came in at $34.1 million, up 40.27% from the prior year.
• Accumulated Expenses fell to $23.5 million in Q2 2026 per FLGT's latest filing, from $34.9 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $34.9 million in Q1 2026 and troughed at $11.8 million in Q1 2022.
• A 5-year average of $24.4 million and a median of $24.1 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2025 and 2026: Accumulated Expenses tumbled 35.61% in 2025, then surged 109.13% in 2026.
• Over 5 years, Accumulated Expenses stood at $25.0 million in 2022, then advanced by 23.04% to $30.7 million in 2023, then slipped by 21.01% to $24.3 million in 2024, then jumped by 40.27% to $34.1 million in 2025, then sank by 30.98% to $23.5 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $23.5 million, $34.9 million, and $34.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.